Sobering Figures: Alcohol's Link to GI Cancer

This transcript has been edited for clarity.
In January 2025, the US Surgeon General released an important advisory that 'highlights alcohol use as a leading preventable cause of cancer in the United States, contributing to nearly 100,000 cancer cases and about 20,000 cancer deaths each year.' This is in line with epidemiologic evidence for the carcinogenicity of alcohol.
However, the advisory also noted that approximately 72% of American adults drink alcohol at least once a week, and fewer than half realize that alcohol use contributes to an increase in cancer risk.
In this video, we will explore the research linking alcohol to gastrointestinal (GI) cancers and suggest ways that physicians and public health experts can help individuals dramatically reduce their alcohol consumption. Through careful discussions in the clinic and public health initiatives, we can hopefully prevent many cancer deaths related to alcohol use.
The Toll of Alcohol-Associated GI Cancer
The association between alcohol consumption and cancer risk was first appreciated during the late 1980s. Over time, a growing body of research has demonstrated 'a causal relationship between alcohol use and increased risk for at least seven different types of cancer, including breast (in women), colorectum, esophagus, liver, mouth (oral cavity), throat (pharynx), and voice box (larynx).'
The advisory publication noted that in 2020, approximately 741,300 patients developed cancer in part due to alcohol. In the United States, there are approximately 20,000 cancer deaths annually related to alcohol consumption, more than the number of alcohol-related motor vehicle collisions each year, which totals 13,500.
Breast cancer makes up 60% of cancer-related deaths for women, while liver cancer (approximately 33%) and colorectal cancer (approximately 21%) make up the most cancer-related deaths for men. These figures should be sobering.
Although the risk of developing cancer in people who consume fewer than two drinks per day is lower compared with higher levels of alcohol ingestion, there are a greater number of people who consume one to two drinks per day. Therefore, the total number of cancer cases is similar. In 2020, 185,100 patients who drank one to two drinks daily developed cancer attributed to alcohol usage, compared with 153,400 patients who consumed four to six drinks per day and 192,900 patients who consumed more than six drinks per day.
A standard drink of alcohol amounts to 5 fluid ounces of wine, 12 fluid ounces of beer, or 1.5 fluid ounces of hard liquor.
Knowledge Gap
The International Agency for Research on Cancer — a specialty arm of the World Health Organization — now classifies alcohol as a Group 1 carcinogen along with tobacco, asbestos, and formaldehyde. In fact, 25 years ago, the US National Toxicology Program announced that alcoholic beverage consumption is carcinogenic.
Yet, there remains a knowledge gap among the American public about the fact that alcohol is a strong cancer risk factor. A 2019 survey indicated that only 45% of Americans realized alcohol is a cancer risk factor, while those surveyed had higher awareness of the cancer risks posed by other factors, such as radiation exposure (91%), tobacco (89%), and asbestos (81%).
Scientists have been studying alcohol as a potential risk factor for cancer over 20 years, using the same template of observational studies that researchers previously applied to studying smoking as a cancer risk factor.
A large global meta-analysis comprising 572 research studies and 486,538 cancer deaths concluded that alcohol is indeed a cancer risk factor. A pooled analysis of 26 studies found the odds of developing oral cancer increased by 40% for those who drank one alcoholic beverage daily compared with those who did not. Furthermore, another meta-analysis showed the relative risk of cancer development compared with people who don't drink was 1.0 for light drinkers, 1.21 for moderate drinkers, and 1.52 for heavy drinkers (ie, more than four drinks per day).
How Alcohol Causes Cancer
Acetaldehyde is a breakdown byproduct of alcohol that can cause cancer by binding to DNA and damaging it. As a result, a cell can begin to grow uncontrollably and produce a cancerous tumor. In addition, alcohol can produce reactive oxygen species, which has the potential to create inflammation through oxidation, also damaging DNA, proteins, and lipids.
Studies have shown that providing ethanol or acetaldehyde, which is the metabolic breakdown product of ethanol, led rats to develop more tumors in the body compared with controls. Alcohol can even increase estrogen levels, which can potentially predispose to breast cancer development.
Smoking while drinking poses additional risks. Carcinogens from tobacco smoke can dissolve in alcohol liquid and more easily enter the body, which is especially concerning for the potential contribution to throat and oral cancers. Acetaldehyde can sometimes be used as a food additive and aroma agent, and is a significant carcinogenic component found in cigarette smoke. The acetaldehyde concentration in cigarette smoke is 1000 times greater than that in other significant carcinogens such as polycyclic aromatic hydrocarbons or nitrosamines from tobacco. Drinking alcohol in combination with smoking cigarettes can have a synergistic negative effect on the risk for colorectal cancer, and the combination can have a sevenfold effect on the upper digestive tract's exposure to carcinogenic acetaldehyde.
Additional research has focused on whether folate deficiency, sometimes caused by heavy alcohol use, might also place patients at risk through an alternative pathway.
Esophageal and Liver Cancer
According to the National Cancer Institute (NCI), heavy alcohol consumption can increase esophageal cancer risk fivefold. Even light drinking can increase the risk by 1.3-fold, highlighting the importance of limiting alcohol consumption.
The NCI also reports that heavy alcohol ingestion can multiply the risk of developing hepatocellular carcinoma and intrahepatic cholangiocarcinoma by two times compared with the regular population.
Although additional research needs to be conducted, it has been hypothesized that alcohol can cause liver cancer by altering the immune response, causing reactive oxygen species production, and producing changes in the immune response.
Unfortunately, alcohol can act synergistically with hepatitis B and C to cause liver cancer.
Also, consistently drinking two or more alcoholic beverages per day is associated with an increased risk for liver cancer.
Gastric Cancer
Recent studies have shown that alcohol consumption could increase gastric cancer risk. Acetaldehydes may act as a possible mechanism by creating a local toxic effect, and ethanol may also disturb gastric mucosal protection.
A meta-analysis that reviewed 10 case-control studies investigating alcohol and gastric cancer risks validated it as a risk factor even at low levels of alcohol consumption. A Korean population-based retrospective cohort study found that 'the risk of GI cancer increased linearly with the frequency of drinking in a dose-dependent manner.'
Pancreatic Cancer
The same Korean study found that the risk for pancreatic cancer increased with weekly alcohol drinking.
A meta-analysis published in the British Journal of Cancer also showed a 20% increase in pancreatic cancer risk with alcohol consumption.
In a study of over 450,000 Americans living in California, Florida, Louisiana, North Carolina, Pennsylvania, and New Jersey, the risk of developing pancreatic cancer in heavy alcohol users (at least three drinks per day) was 1.35 compared with light users (less than one drink per day) in never smokers.
Another study, of over 33,000 patients in Sweden, found the relative risk of pancreatic cancer for intermediate and heavy alcohol use was 2.13 in former smokers.
Colorectal Cancer
In 2025, the NCI published a guide indicating that moderate to heavy alcohol consumption is associated with a 1.2- to 1.5-fold increased risk for colorectal cancer compared with patients who were abstinent.
In an earlier review, from 2015, researchers showed that alcohol consumption of more than 30 grams per day was associated with an increased risk of developing colorectal cancer. Estimates from the World Cancer Research Fund/American Institute for Cancer Research indicate that there was a 9% risk of developing colorectal cancer for every 10 grams of alcohol consumed daily.
In addition, folate deficiency has been shown to worsen the effects of drinking alcohol on colorectal cancer risks.
A 2022 meta-analysis published in Clinical Gastroenterology and Hepatology found that consuming alcohol was associated with a 1.71 relative risk of developing early-onset colorectal cancer. Interestingly, cigarette smoking was not statistically significant for establishing such an association. Consumption of processed meat and fried foods, as well as lack of exercise, also contributed to the development of early-onset colorectal cancer. As physicians, we should encourage patients to make lifestyle modifications to avoid those other risk factors.
While additional research needs to be conducted, a cohort study in California and Hawaii, led by Dr Song-Yi Park, indicated that the relationship between alcohol and colorectal cancer might vary by ethnicity. In addition, it found that colorectal cancer risk was increased by wine and beer, but not liquor. The association with alcohol was greatest for rectal and left colon cancers.
Public Health Approaches
Alcohol is the most consumed drug in the United States, a statistic that requires validated approaches for addressing.
In the future, Congress can vote to include alcohol warning labels on bottles and cans. There's evidence that health warning labels are effective in teaching the public about alcohol-induced health consequences. Interestingly, multiple studies have illustrated a decrease in alcohol consumption following viewership of alcohol warning labels. In addition, alcohol warning labels depicting liver cancer or negative alcohol consequences have been shown to reduce drinking and drunk driver situations.
A 2024 meta-analysis showed with 'moderate certainty' that alcohol warning labels might decrease selection of alcoholic drinks and drinking before driving. However, there was 'low evidence' demonstrating that warning labels might reduce alcohol drinking per occasion, or alcohol drinking speeds, which would be important considerations at parties and social gatherings.
A 2020 study showed that alcohol selection was lower for all kinds of alcohol warning labels compared with no warning labels. Specifically, alcoholic drink selection was 56% with warning labels that consisted of an image and text, 49% for image only, and 61% for text only.
During the 1990s and 2000s, physicians and public health experts learned a lot about how to motivate patients to quit smoking. One successful public health approach was the use of the transtheoretical model, where patients go through various stages, such as precontemplation, contemplation, preparation, action, and maintenance, when trying to decide when to quit smoking. This behavioral modification model could be used for alcohol prevention too.
Key public policy interventions also helped, including a tobacco taxation, advertising bans, and tobacco marketing restrictions in smoke-free zones. Similar interventions could work well for alcohol. Alcohol taxation can be used to deter heavy drinkers and young drinkers who don't have as much money to spend, given that tobacco taxation was successful for smoking reductions.
Furthermore, policies could be set to maintain minimum unit pricing to prevent the sale of ultracheap liquor. States could also limit the hours of alcohol purchasing or even the days, such as banning alcohol sales on Sunday. These public health strategies could work in tandem to help decrease alcohol drinking rates in the United States.
Alcohol and smoking are very similar social activities that for years were depicted as stylish and cool in movies and on TV. Then smoking ads were banned on TV through the Public Health Cigarette Smoking Act of 1970. During the 1970s, cigarette companies shifted their advertising from TV to print.
So, it would be important in the future to ban alcohol ads from all media and printed marketing.
As highlighted by the World Health Organization, advertising bans and restrictions were helpful in Nordic countries with decreasing the per-capita drinking amount.
Finally, physicians should screen patients for heavy alcohol consumption using the validated AUDIT- C questionnaire and biomarkers such as phosphatidyl ethanol. When needed, Alcoholics Anonymous or a similar 12-step program can be offered to patients who drink heavily to reduce alcohol consumption.
Tips to Reduce Alcohol Consumption
Here are some helpful tips to encourage patients and friends to reduce alcohol consumption.
Set a quit date and avoid triggers such as meeting friends at bars.
Drink mocktails at social gatherings and parties. Patients can also choose from a plethora of innovative and tasty alcohol-free beers when drinking with friends. Several beer companies, such as Heineken, Budweiser, Guinness, and Samuel Adams, have developed great alcohol-free beer alternatives, which are extremely helpful for patients trying to remain abstinent and also for those trying to prevent cancer.
Mass media initiatives such as the Ad Council and celebrity public service announcement television spots could be used to shift social norms around alcohol consumption. Public service announcements could also be shared at sporting events and concerts where alcohol consumption is common.
Public health campaigns could place posters in bars and liquor stores informing consumers about the link between alcohol and cancer.
Social media could teach target populations about alcohol reduction in fun and engaging ways.
By talking with patients in clinic and working on public health campaigns, gastroenterologists have a unique opportunity to inspire behavioral lifestyle changes in patients and to prevent many cancers.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Medscape

22 minutes ago

• Medscape

Fast Five Quiz: Drowning

Drowning is a significant cause of mortality. In the United States, it is the leading cause of death among children aged 1-4 years. Even when not fatal, drowning can result in permanent and severe disability due to prolonged hypoxia. Globally, drowning deaths decreased by 38% between 2000 and 2024. However, in the United States, the drowning mortality rate increased from 2019 to 2022. On average, 11 drowning deaths per day occur in the United States. Do you know the latest facts surrounding drowning? Check your knowledge with this brief quiz. There are major racial/ethnic disparities in drowning deaths and swimming ability in the United States. Although Alaska Native/non-Hispanic American Indian peoples and Black people have the highest drowning rates, the lowest rate of swimming lessons is among Hispanic adults, at only 28.1%. Comparatively, 36.9% of Black adults and 51.8% of White adults have taken swimming lessons. The overall rate of swimming lessons among all US adults is 45.3%. Learn more about drowning epidemiology. A global review on drowning prevention among children and young people found several effective strategies. In addition to placing barriers around bodies of water, the review also found wearing personal flotation devices and removing or covering water hazards to be effective in drowning prevention. Use of solar pool covers was deemed a harmful strategy because unsupervised children have become trapped under these covers and drowned. There have also been cases of drowning deaths among infants placed in baby bath seats in bathtubs. Community-based water safety awareness campaigns were rated as "promising" in the review. Although several campaigns have resulted in increased rates of personal flotation device ownership, the results vary according to the nature of the campaign and its audience. Some campaigns were noted to lack a statistically significant positive impact. Learn more about patient education on drowning. A retrospective cohort study of 406 pediatric drowning patients found that the absence of prehospital cardiac arrest, along with transfer to a high-volume hospital and indoor drowning location, were factors significantly associated with a good clinical outcome. In the study, only one patient died among the 218 patients without prehospital cardiac arrest. However, only five patients had good outcomes among the 188 patients with prehospital cardiac arrest. Patient sex, age, and prehospital time since drowning event were not significantly associated with clinical outcome. Learn more about drowning prognosis. According to American Heart Association/American Academy of Pediatrics guidelines, in-water rescue breathing should be provided to drowning victims by trained rescuers if safe. Guidelines from the Wilderness Medical Society concur. It is not necessary to wait until the patient is on dry land or in a vessel before commencing rescue breathing. Resuscitation of drowning patients should not focus on chest compressions alone. Ventilation and airway management are crucial because cardiac arrest often follows severe hypoxemia in drowning cases. Although it is prudent for water recreation areas to provide automatic external defibrillators, most drowning victims who enter cardiac arrest do not present with defibrillation-responsive rhythms. The Heimlich maneuver is not recommended in drowning because efforts to expel water from the lungs delays resuscitation and might increase the risk for vomiting and aspiration. Learn more about prehospital care in drowning. The Wilderness Medical Society does not recommend empirical antibiotics in the initial management of drowning patients. Although pneumonia might result from aspirated water, the causative microorganisms are often atypical and unresponsive to empirical antibiotic therapies. Additionally, inflammatory pneumonitis resulting from water aspiration and the stress of the drowning event may be mistaken for symptoms of infectious pneumonia. Ideally, before antibiotic administration, pneumonia should be confirmed by urinary antigen testing, sputum cultures, and/or blood cultures. Learn more about the disposition of drowning victims.

Yahoo

22 minutes ago

• Yahoo

Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions

– Results from the study continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit – – All 12 patients with at least one year of follow-up who received a full dose of zimislecel as a single infusion achieved ADA-recommended target HbA1c levels <7% and >70% time-in-range (70-180 mg/dL), and 10/12 patients were insulin free – – Data presented at ADA simultaneously published in the New England Journal of Medicine – – Vertex to host investor webcast tonight, June 20, 2025, at 7:15 p.m. CT / 8:15 p.m. ET – BOSTON, June 20, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the American Diabetes Association (ADA) annual conference in Chicago as part of the symposium, "Innovation and Progress in Stem Cell-Derived Islet-Cell Replacement Therapy," from 6:15-6:30 p.m. CT (abstract 2025-A-1921) and published online by the New England Journal of Medicine. The data are from 12 patients who received the full dose of zimislecel as a single infusion and were followed for at least one year, as of October 2024. Results from the study to date continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit with longer follow-up. All 12 participants: Demonstrated engraftment with glucose-responsive endogenous C-peptide production, which was durable through one year of follow-up. Achieved the ADA targets of HbA1c <7% and time in range of >70%. Were free of SHEs from day 90 onwards. Had a reduction in exogenous insulin use (mean reduction in daily insulin dose: 92%). 10/12 (83%) no longer required exogenous insulin at Month 12. Achieved the Phase 1/2 primary endpoint of elimination of SHEs with HbA1c <7%. Zimislecel continues to be generally well tolerated. Most adverse events (AEs) were mild or moderate, and there were no serious AEs related to zimislecel treatment. As previously reported, two patient deaths occurred, both unrelated to treatment with zimislecel. The safety profile is generally consistent with the immunosuppressive regimen used in the study, the infusion procedure, and complications from long-standing diabetes. "These data on the first fully differentiated, stem cell-derived, off-the-shelf islet cell therapy continue to be unprecedented. The magnitude, consistency and durability of the results from all 12 patients with more than one year of follow-up reinforce the transformative potential of zimislecel for people living with T1D complicated by severe hypoglycemia," said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. "We are excited to complete enrollment and dosing in the Phase 1/2/3 Program and look forward to potential regulatory submissions next year." "It's remarkable to see 12 out of 12 patients with baseline HbA1c above 7% and multiple severe hypoglycemic events reach consensus targets for glycemic control by both HbA1c and time in range as well as elimination of severe hypoglycemic events," said Michael R. Rickels, M.D., M.S., Medical Director, Pancreatic Islet Cell Transplant Program, Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases, Presenting Author and Steering Committee Co-Chair for the zimislecel clinical program, and author on the New England Journal of Medicine paper. "As I think about my patients and the unmet need in the type 1 diabetes community, the results we've seen so far for restoring endogenous insulin secretion with a stem cell-derived islet therapy bring me hope and confidence for a transformative treatment option for individuals with type 1 diabetes in the not-so-distant future." About Type 1 DiabetesT1D results from the autoimmune destruction of insulin-producing beta cells in pancreatic islets. Insulin deficiency results in hyperglycemia and can lead to acute life-threatening complications such as diabetic ketoacidosis. People with T1D are reliant on lifelong treatment with exogenous insulin that requires careful monitoring of blood glucose levels. Even with the availability of advanced exogenous insulin delivery and glucose monitoring systems, people with T1D can have periods of very low and very high blood sugar levels. Exogenous insulin has a narrow therapeutic range and carries an inherent risk of causing low blood sugar levels or hypoglycemic events, which can potentially result in arrhythmias, seizures, coma and even death. Due to the limitations and complexities of exogenous insulin treatment, it can be difficult for people with T1D to achieve and maintain good glucose control. Exposure to prolonged periods of high blood glucose levels, or hyperglycemia, can lead to long-term complications such as nerve damage, kidney disease/failure, eye disease (including vision loss), cardiovascular disease, stroke and even death. HbA1c is a measure of average blood glucose over the most recent ~2-3 months, and the consensus guidance is to maintain an HbA1c of <7% to reduce the risk of long-term complications; only ~1 in 4 people with T1D globally meet this clinical target. Current standards of care do not address the underlying cause of the disease and leave people with T1D susceptible to both hypo- and hyperglycemia and their associated morbidity and mortality. There is no cure for T1D. About ZimislecelZimislecel (VX-880) is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. Zimislecel is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. Zimislecel has the potential to restore the body's ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. Zimislecel is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. The zimislecel trial has expanded to additional sites that are currently active and enrolling in the U.S., Canada and Europe. Zimislecel has been granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration, Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), and has secured an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Zimislecel is investigational and has not been approved by health authorities globally. About VertexVertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. Special Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, (i) statements by Carmen Bozic, M.D., and Michael R. Rickels, M.D., M.S., in this press release, (ii) plans, expectations for, and the potential benefits of zimislecel, (iii) expectations for the Phase 1/2/3 clinical trial for zimislecel, including expectations for the trial to complete enrollment and dosing, and (iv) plans for potential regulatory submissions next year. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from a limited number of patients may not be indicative of final clinical trial results, that data from the company's research and development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy, that timelines for regulatory submissions may be longer than anticipated, and other risks listed under the heading "Risk Factors" in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Investor Event and Webcast Vertex will host an investor event on Friday, June 20, 2025, at 7:15 p.m. CT/8:15 p.m. ET, in Chicago, to discuss the positive zimislecel data in type 1 diabetes. A live webcast of the presentation and Q&A portions can be accessed through the Investor Relations section of Vertex's website at An archived webcast will be available on the company's website. View source version on Contacts Vertex Pharmaceuticals IncorporatedInvestors: InvestorInfo@ Media: mediainfo@ orInternational: +44 20 3204 5275

CBS News

22 minutes ago

• CBS News

Pennsylvania family who stayed at Ronald McDonald house shares their continued message of hope

Bucks County family who stayed at the Ronald McDonald house shares their continued message of hope Bucks County family who stayed at the Ronald McDonald house shares their continued message of hope Bucks County family who stayed at the Ronald McDonald house shares their continued message of hope "Sarah's Painting" was created in a hospital bed by a 9-year-old going through chemotherapy. Michael Pulaski said his daughter, Sarah, loved to paint. "Which was kind of news to us, and she was actually pretty good!" Michael Pulaski said with a chuckle and smile. "It meant something to her, so it meant something to us." Now this picture is taking on a bigger meaning. "Sarah's Painting" CBS News Philadelphia. "It's been, for years, my method of communicating with the world," Sarah's brother, Ryan Pulaski, said. The 22-year-old college student is in the process of making an album. His first single was released Friday, on what would be Sarah's 25th birthday. "In Sarah's Painting, I see visions of life it should be," he sings in the song called "Sarah's Painting." It's inspired by the colorful brush strokes frozen in time. "I feel exceptionally called to create art, and it is only because I had, I have this wonderful sister who was an artist herself, that I was able to find my own voice," Ryan Pulaski said. Pulaski family. In 2010, CBS News Philadelphia caught Sarah's infectious smile on camera while walking the halls of the Children's Hospital of Philadelphia. She talked with us about a Ronald McDonald house family room for the telethon. "When we first met you, it was actually a stressful but promising time, because Sarah was in her first portions of treatment, and she was doing well," Michael Pulaski said. The pre-teen from Richboro went into remission, but later relapsed. At 11 years old, she died after a brave, long battle with leukemia. "This is my absolute favorite picture of the two of them together," Michael Pulaski said, pointing at a photo of Ryan and Sarah. Pulaski family. It's an unbreakable sibling bond — shining through photos, "Sarah's Painting," and now Ryan's song. "She'd probably tell me, I still can't sing," Ryan Pulaski said with a laugh. He continued, "But I think she would love it and be supportive all the same." As for the sibling's dad, "There aren't words, and I'm just proud." The Pulaski family said this story — it's one full of hope, to show others, a picture is worth a thousand words, a thousand memories and a love that lasts a thousand lifetimes. "I think if my 22-year-old son, who's had a probably a more difficult journey than I have, can find hope and joy, then I think the rest of us can too," Michael Pulaski said.